CIK 0001390478 · Non-accelerated filer<br>Smaller reporting company
SELLAS Life Sciences Group, Inc.
Sign in to watch- Ticker
- SLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6462005278
- Business address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
- Former names
- GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award President and CEO acquired 95,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award VP, Finance & Corp Controller acquired 15,000 shares (grant or award)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 8-K Event Results of operations
- 10-K Report Annual Report
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- 424B5 Offering Prospectus
- 8-K Event Material agreement · Agreement ended · Unregistered share sale
- 8-K Event Material agreement · Shareholder rights changed
- 8-K Event Other events
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
Page 15 of 64 · 1,276 filings